Paraneoplastic Syndromes
7
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (7)
A Case Report of NMDAR Encephalopathy
Immunotherapy of the Paraneoplastic Syndromes
CICLOPS Immune Checkpoint Inhibitors Neurotoxicity: Long-term Outcomes, Predictors, and Survival.
Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
CASPR2 Encephalitis Initial Symptoms
Tumor Characteristics in Patients With Paraneoplastic Neurological Syndromes (PNS)
The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes